Standard BioTools' Strategic Overhaul Fuels Biotech Merger Ambitions

BOSTON, MA – July 28, 2026 – In a series of calculated maneuvers designed to reshape its future, Standard BioTools Inc. today announced a strategic divestment and a significant cash infusion, clearing the runway for its pending merger with clinical-stage drug developer Treeline Biosciences. The life science tools company will sell its Mass Cytometry business and has secured a $30 million payment from Illumina, moves that sharpen its focus and materially strengthen its financial position ahead of the transformative deal.

These are not isolated transactions but interconnected pieces of a complex strategy to optimize the company's valuation in the all-stock merger with Treeline. The announcements, which came alongside news of an early antitrust clearance from the Federal Trade Commission, signal that Standard BioTools is aggressively streamlining its operations to emerge as a well-capitalized biopharmaceutical powerhouse. For investors and industry observers, the moves offer a clear lesson in corporate re-engineering, where legacy assets are monetized to fuel next-generation ambitions.

Fortifying the Balance Sheet for Transformation

The financial engineering at the heart of today’s news is pivotal. Standard BioTools confirmed it received approximately $30 million from Illumina, representing a full buyout of a 2026 earnout and all future royalty payments tied to Illumina’s prior acquisition of the SomaLogic business. This injection of non-dilutive cash is critical, as it directly bolsters the company’s “pro forma net cash position.”

This metric is more than just an accounting term; it is a key determinant in the final exchange ratio of the Treeline merger. The agreement values Treeline at $2.5 billion and Standard BioTools at an initial $460 million, but the latter's valuation is subject to adjustment based on its net cash at closing. By converting a future, uncertain revenue stream into immediate cash, Standard BioTools enhances its value in the final calculation, securing a more favorable position for its current stockholders, who are expected to own approximately 16% of the combined entity.

In parallel, the company has agreed to sell its Mass Cytometry business—including the well-regarded CyTOF and Hyperion product lines—to Multiplex Bio. The deal is valued at up to $10 million, structured as a seller's note and a potential milestone payment. However, the transaction also includes a provision for Standard BioTools to provide a working capital loan of up to $10 million to the new entity. This reveals the hidden cost of the divestiture: while it streamlines the portfolio, the immediate cash benefit is complex and carries the risk associated with a loan. The primary benefit is strategic, removing a non-core asset to present a cleaner, more focused entity to the market ahead of the merger.

A New Steward for a Scientific Legacy

The sale of the Mass Cytometry business is not just a financial transaction but the birth of a new, highly focused player in the spatial biology market. Multiplex Bio, the acquiring entity, was founded by a team of industry veterans: Drs. Michael Johnson and Tom Villani, who previously co-founded and sold the advanced imaging firm Visikol to BICO, and Charles Coffman, an expert in scaling life science operations.

Multiplex Bio’s leadership signals a commitment to not only maintaining but advancing the CyTOF and Hyperion platforms. "The Standard BioTools Mass Cytometry business has an extraordinary scientific legacy and we are honored to carry it forward," said Dr. Johnson, who will serve as CEO of the new company. "Our team has operated this technology firsthand and we understand deeply what it means to the customers and researchers who rely on it."

This move addresses a key concern in any technology divestment: continuity. Multiplex Bio intends to retain the majority of the existing team and honor all customer service and maintenance commitments, even continuing to operate under the Standard BioTools brand for a transitional period. This strategy is designed to reassure a loyal scientific user base that the platforms foundational to single-cell and multiplex proteomic research will be stewarded by a dedicated team with deep domain expertise. For Standard BioTools, it ensures a responsible handoff of a legacy technology while it pivots toward its new identity.

Michael Egholm, PhD, President and CEO of Standard BioTools, expressed confidence in the transition, stating, "After a comprehensive evaluation of opportunities for this business, we are confident that Michael, Tom and Charles are uniquely positioned to steward our products and team given their scientific depth, commercial, operational experience and passion for the technology."

The End Game: Powering Treeline's Clinical Ambitions

Ultimately, these strategic decisions are in service of a much larger goal: the successful merger with Treeline Biosciences and its transformation into a publicly traded, clinical-stage oncology company. Led by Dr. Josh Bilenker, the founder of Loxo Oncology, Treeline brings a deep pipeline of small molecule inhibitors and protein degraders aimed at high-value targets in cancer, neurology, and immunology.

With three programs already in Phase 1 trials and promising early data from its BCL6 degrader, TLN-121, Treeline represents the kind of high-science, high-potential pipeline that requires substantial capital. The merger provides just that. The combined company, to be named Treeline Biosciences Holdings, Inc., is expected to have over $900 million in pro forma cash at closing, providing a financial runway projected to last into 2029.

By shedding the Mass Cytometry business and crystallizing the Illumina earnout, Standard BioTools is effectively converting its diversified, tool-based structure into a pure-play capital vehicle to fuel Treeline’s ambitious drug development programs. The early termination of the Hart-Scott-Rodino waiting period removes a key regulatory hurdle, keeping both the divestiture and the merger on track for a close by the end of 2026, pending stockholder approvals. This allows the new entity to hit the ground running, focused entirely on advancing its therapeutic candidates through the clinic and toward potential market entry.